Publication details
Cirkulující mikroRNA v moči jako biomarker mnohočetného myelomu
| Title in English | Circulating microRNA in urine as biomarker of multiple myeloma |
|---|---|
| Authors | |
| Year of publication | 2015 |
| Type | Conference abstract |
| MU Faculty or unit | |
| Citation | |
| Attached files | |
| Description | Introduction: MicroRNAs (miRNAs) are 21 to 23 nt long, single-stranded RNAs, which are involved in regulation of gene expression and also participate in the pathogenesis of cancers, including multiple myeloma (MM). Circulating miRNAs are present in various body fluids such as serum, plasma, urine, saliva, or breast milk, they are very stable, quantifiable, resistant to the action of RNase and thus have the potential to be a diagnostic marker in MM. Since the MM is a systemic disease affecting other organs such as the kidney, it is possible that circulating miRNA found in urine correlate with disease. This finding would allow non-invasive diagnosis of MM and overcoming existing painful procedure, based on the collection of bone marrow (BM). The aim of this study was therefore to identify circulating miRNA in urine, which are able to distinguish patients with MM from healthy donors (HD), and compare the levels of expression of deregulated miRNAs with clinical parameters. Material and methods: In total, the study included 76 urine specimens. The initial analysis was performed using the platform Serum / Plasma Focus PCR MicroRNA Panel (Exiqon) on urine samples 8 newly diagnosed patients and 8 MM HD. Selected differentially expressed miRNAs (p <0.05) between groups were verified by qPCR using the relative quantification using cel-miR-39 in 30 newly diagnosed MM, 15 HD and 15 patients with renal cell carcinoma (RCC). Results: Moderately revealed 20 deregulated miRNAs (p <0.05 for all miRNA) between MM and HD. For validation were selected 8 most deregulated miRNAs whose expression levels were further validated in a larger sample. Were included in the analysis, patients having RCC to distinguish specific miRNAs associated with MM. Based on the results of the only level of miR-22 significantly increased in the urine of patients with MM in comparison with HD (p <0.012) and compared with urine samples of patients with RCC (p <0.009). A similar trend was also observed for miR-25, whose level in urine was significantly increased in patients with MM in comparison with RCC patients (p <0.007), but compared to samples HD its level did not differ significantly (p = 0.325). Correlation with clinical parameters is in progress. Conclusion: Our preliminary results indicate that miR-22 circulating in the urine could have the potential to become a diagnostic biomarker for patients with MM. |